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Summary
Hyperhomocysteinemia, which is a recognized indepen-
dent risk factor for premature vascular occlusion, is de-
fined as a fasting total plasma homocysteine (tHcy) level
115 mM. There may also be graded increased risks for
persons with tHcy concentrations of 10–15 mM. The
measurement of tHcy requires precise sample collection,
immediate separation and freezing of plasma, and
referral to a specialized laboratory. The etiologies of
hyperhomocysteinemia are complex and involve both
genetic and environmental factors. Because the inappro-
priate supplementation of involved cofactors can be
harmful, it is important to identify the cause of hyper-
homocysteinemia prior to treatment.
Introduction
It has been known for some time that the concentrations
of homocystine and homocysteine are increased in blood
and urine in (a) cystathionine b-synthase deficiency, (b)
methylenetetrahydrofolate reductase (MTHFR) defi-
ciency, and (c) defects in the synthesis of cobalamin (vi-
tamin B12) cofactors. The large increases in the concen-
trations of homocystine in these conditions are easily
detected by the ion-exchange chromatography methods
used to measure amino acids in most laboratories. In
recent years, however, it has been found that much
smaller increases in total plasma homocysteine (tHcy)
concentrations are found in pyridoxine, cobalamin, and
folate deficiencies and, under certain conditions, in sub-
jects with a heat-labile form of MTHFR. Furthermore,
even a slightly increased tHcy level is a risk factor for
the development of coronary, cerebral, and peripheral
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vascular disease, as well as venous thrombi, and the
increased risk is independent of other risk factors such
as hyperlipidemia, hypertension, diabetes mellitus, and
smoking. Laboratories are thus now being asked to dis-
tinguish between normal tHcy concentrations and those
that put patients at increased risk for these conditions.
The following paragraphs review the methods available
to make this distinction, and they provide some guide-
lines to define and manage hyperhomocysteinemia.
Measurement of tHcy
The structures of homocysteine, homocystine (homo-
cysteine-homocysteine disulfide), and homocysteine-cys-
teine disulfide are shown in figure 1. Approximately
70% of the homocysteine in plasma or serum is bound
to cysteine residues in albumin and other plasma pro-
teins, and only trace amounts exist as free homocysteine
and in homocystine and homocysteine-cysteine disulfide.
The methods that are used to measure free amino acids
in most laboratories cannot detect the small amounts of
these compounds present in normal blood, nor can they
detect the small increases that may put patients at in-
creased risk for premature cardiovascular disease. That
level of sensitivity can only be achieved by addition of
a reducing agent, such as dithiothreitol (DTT) or beta-
mercaptoethanol, to freshly obtained plasma, to release
homocysteine from plasma proteins and other thiols,
before direct measurement of what is then termed
“tHcy.”
The accuracy and reproducibility of tHcy testing is
dependent, first, on precise sample collection and han-
dling; the blood samples must be placed on ice imme-
diately to prevent the release of free homocysteine from
erythrocytes, and samples should be centrifuged, and the
plasma frozen, X30 min after collection. The tHcy is
then stable for relatively long periods of time (i.e.,
months).
All of the methods that have been developed to mea-
sure tHcy after addition of a reducing agent give similar
normal values of 5–15 mmol/liter (or mM) (Ueland et al.
1993). Although ion-exchange chromatography on an
amino acid analyzer can be used to do this, most lab-
oratories that process large numbers of samples use
methods based on high-performance liquid chromatog-
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Figure 1 Molecular structures of homocysteine, homocystine, and homocysteine-cysteine disulfide
raphy (HPLC) or stable isotope–dilution gas chroma-
tography–mass spectrometry (GC-MS).
Although methods to measure tHcy by HPLC are still
evolving, most of them are designed to detect fluorescent
derivatives of homocysteine bound covalently to a chro-
mophore. The most easily automated of these uses sam-
ple reduction with tri-n-butylphosphine, followed by
chromatography of sulfhydril-containing compounds
such as the sulfobenzooxadiazole (SBD) derivatives (Ar-
aki and Sako 1987). Other fluorescent derivatives may
also be used, but the o-phthaldehyde derivative of homo-
cysteine is less stable and must be injected into the HPLC
shortly after it is made, and monobromobiamine, an-
other derivatizing reagent (Jacobsen et al. 1989, 1994),
is itself fluorescent and can produce chromatographic
peaks that may complicate the analysis. Other HPLC-
based methods, such as those that use a gold-mercury
electrode to detect underivatized thiols or that convert
homocysteine to S-adenosyl-methionine, are used less
frequently.
tHcy concentration may also be measured by stable
isotope–dilution GC-MS with selected ion monitoring.
In this system, deuterated (usually) homocysteine is
added to the specimen as an internal standard before
reduction and derivitization, and homocysteine is mea-
sured after capillary GC-MS, by measurement of the
extent to which the internal standard is diluted by homo-
cysteine in the sample. Although the high cost of the
instrumentation has made the use of this system less
common than the use of HPLC, a relative advantage is
that methionine, methylmalonic acid, and cystathionine,
compounds that are important in differential diagnosis,
can be measured at the same time (Stabler et al. 1987,
1993).
Clinical Correlates
The Hordaland study (Nygaard et al. 1995) and the
physicians’ health trial (Stampfer et al. 1992), as well as
a metanalysis of 27 studies (Boushey et al. 1995), found
that tHcy values 115 mM confer an increased risk for
premature vascular occlusion and that values of 10–15
mM may confer a graded risk. It is appropriate to use
15 mM as an initial threshold for the diagnosis of hy-
perhomocysteinemia, although the value may be revised
downward as more data are collected. Because of both
the inherent complexity of testing and the importance
of correct sample collection and processing, a patient
with a single elevated tHcy value should be retested after
a fast of x8 h.
The basis of fasting tHcy levels 115 mM should always
be determined. It is important to measure serum and
erythrocyte folate, serum cobalamin, and serum and/or
urine methylmalonic acid levels. Supplementation with
folate alone can obscure a diagnosis of cobalamin de-
ficiency, by masking hematologic findings while allowing
neurological damage to progress (Savage and Linden-
baum 1995). Genetic factors that may contribute to ele-
vations of tHcy include heterozygosity for severe forms
of several inborn errors—among them cystathionine b-
synthase deficiency, MTHFR deficiency, and methionine
synthase deficiency—and the cblC, cblD, cblE, and cblF
defects of methylcobalamin biosynthesis. In addition,
common polymorphisms for MTHFRmay contribute to
elevated tHcy, particularly when nutritional folate status
is marginal.
Therapy should be based on knowledge of etiology
and pathogenesis. Relatively small (e.g., X1 mg/mo)
doses of parenteral cobalamin can be given to persons
with cobalamin malabsorption or deficiency, whereas
patients with blocks in methylcobalamin biosynthesis
may require milligram doses daily. Similarly, folate
deficiency secondary to sprue can be treated with oral
folate, whereas patients with hereditary folate malab-
sorption require reduced folates in high doses given par-
enterally. Deficiency states will probably require greater
amounts than the RDA, for both vitamins. The efficacy
of therapy can be monitored by measurement of tHcy
and, if cobalamin deficiency or (appropriate) biosyn-
thetic defect is present, of urine or blood methylmalonic
acid.
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Disclaimer
This guideline is designed primarily as an educational
resource for medical geneticists and other health-care
providers, to help them provide quality medical genetic
services. Adherence to this guideline does not necessarily
ensure a successful medical outcome. This guideline
should not be considered inclusive of all proper proce-
dures and tests or exclusive of other procedures and tests
that are reasonably directed toward obtaining the same
results. In determining the propriety of any specific pro-
cedure or test, the geneticist should apply his or her own
professional judgment to the specific clinical circum-
stances presented by the individual patient or specimen.
It may be prudent, however, to document in the patient’s
record the rationale for any significant deviation from
this guideline.
American Society ofHumanGenetics/American
College of Medical Genetics Test and Technol-
ogy Transfer Committee Working Group
Stephen I. Goodman, University of Colorado School ofMed-
icine, Denver; Louis J. Elsas, Emory University School of Med-
icine, Atlanta; and David S. Rosenblatt, McGill University,
Montreal.
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